<DOC>
	<DOC>NCT01291134</DOC>
	<brief_summary>The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).</brief_summary>
	<brief_title>PureGen: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Persistent neck and/or arm pain consistent to symptomatic cervical degenerative disc disease Moderate Neck Disability Index Unresponsive to conservative treatment for at least 6 weeks More than 4 levels requiring surgical treatment Prior failed fusion surgery at the index level(s) Systemic or local infection in the disc or cervical spine, past or present Active systemic disease Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing Known or suspected history of alcohol and/or drug abuse Involved in pending litigation or worker's compensation relating to the spine Pregnant or plans to become pregnant during the duration of the study Insulindependent diabetes mellitus Life expectancy less than study duration Any significant psychological disturbance that in the opinion of the Investigator could impair consent process or ability to complete selfassessment questionnaires BMI greater than 40 Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of nonsteroidal antiinflammatory drugs Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>